PERSONAL INFORMATION

Gina MANDA

„Victor Babes" National Institute of Pathology

+40 21 3194528 +40 744246887

gina.manda@gmail.com

www.ivb.ro

Sex F | Date of birth 26/08/1961 | Nationality Romanian

POSITION WITHIN THE PROJECT

Partner responsible

WORK EXPERIENCE

1993 - onwards

„Victor Babes" National Institute of Pathology, 99-101 Splaiul Independentei, 050096 Bucharest, Romania

- Scientific researcher grade I (since 2016)
- Head of Radiobiology Laboratory (2009-2023, 2024-)
- Head of the Nuclear Unit (since 2014)
- Member of the Scientific Council (since 2009)
- Scientific secretary (2009-2013)
- Responsible with QA in research (2009-2013)

Former scientific positions:

- Scientific researcher grade II (1999-2016)
- Scientific researcher grade III (1996-1999)
- Research assistant (1993-1996)

▪ Coordinator of research projects in the field of radiobiology, preclinical screening of drugs, immunology, neurosciences

Type of sector: biomedical research

1987 - 1993

Research assistant
PhD student (1990-1996)

„Ion Cantacuzino" Institute, 103 Splaiul Independentei, Bucharest, Romania

▪ team member in research projects in the field of immunology and immunomodulation
Type of sector: biomedical research

1986 - 1988

Research assistant

Institute for Energetic Nuclear Power Plants, Mioveni, Jud. Ages, Romania

▪ dosimetry
Type of sector: nuclear research

Manda

EDUCATION AND TRAINING

1990 - 1996

PhD

Faculty of Physics, University of Bucharest, Romania

- Biophysics: biology of reactive oxygen species in health and disease

1992

Specialization in autoimmunity

INSERM U354, Paris, France (Prof. Raymond Frade). Specialization in autoimmunity - the idiotype network of the complement receptor CR1 in rheumatoid arthritis

1984 - 1985

Master

Faculty of Physics, University of Bucharest, Romania

- Polymer physics: electrical properties of liquid crystals

1980 - 1984

Bachelor in physics

Faculty of Physics, University of Bucharest, Romania

- Physics

PERSONAL SKILLS

Mother tongue(s): Romanian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
	Replace with name of language certificate. Enter level if known.				
French	C2	C2	B2	B2	B2

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
Common European Framework of Reference for Languages

Communication skills

Excellent scientific communication gained in multi-disciplinary research projects, both national and international (more than 100 oral communications).
Excellent communication as trainor gained in European training projects having as target groups medical doctors working in the Romanian health system or PhD students in the biomedical field.

Organisational / managerial skills

"Victor Babes" National Institute of Pathology, Bucharest, Romania
2003-2013: Responsible for quality management in research (~60 researchers)
2009-2013: Scientific secretary of the institute (~60 researchers)
2009-2023 Head of Radiobiology Laboratory (5-11 researchers)
2009-2019 Coordinator of the functional team Drug development and (immune)toxicology (~18 researchers)
2009 – until now, Member of the Scientific Council of Victor Babes National Institute

Job-related skills

Technical expertise

- excellent command of cell cultures and functional cellular tests
- excellent command of radiobiologic techniques with radiolabelled biomolecules
- good command of flow cytometry and ELISA

Digital competence

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving

Manda

Proficient user	Proficient user	Proficient user	Basic user	Basic user

Levels: Basic user - Independent user - Proficient user
Digital competences - Self-assessment grid

- good command of office suite (word processor, spread sheet, presentation software)
- good command of statistical processing of biomedical data.

ADDITIONAL INFORMATION

H-Index	H-Index = 24 (Google Scholar); H-Index = 23 (Scopus)
Publications	>160 publications (Google Scolar). 113 ISI-indexed publications See the appended List of selected publications
Citations	3760 Google Scholar citations (2830 since 2019), 1817 ISI Web of knowledge citations (without sel-citations)
Project coordination	Project coordinator of 13 scientific projects (3 international and 10 national projects) and project co-director in 12 scientific projects, member of the management team in 2 COST Actions (WG vice-leader in one project, Vice-chair and Scientific representative of the Grant Holder in the 2nd COST Action) in one of these projects) and a management position in two European projects dedicated to Romania for training
Evaluator	Evaluator at national research projects calls Evaluator for the COST programme since 2014 Evaluator for the following journals: Journal of Cellular and Molecular Medicine, International Journal of Molecular Sciences, Oxidative Medicine and Cellular Longevity, British Journal of Cancer, Toxins, Journal of Neurology & Neuromedicine, Journal of Mental Health and Clinical Psychology, Molecular Life, Biophysical Reviews, Colloids and Surfaces B: Biointerfaces, Beilstein, Cell
Management courses	2007 Development of projects financed from European and international funds, Predeal, Romania 2007 Training of Assessors for „IPMA Model for Project Excellence", Bucharest, Romania 2017 Technology transfer course, Bucharest, Romania 2019 Radiologic security for practices with ionizing radiation sources, Magurele, Romania

ANNEXES

List of selected publications (books and scientific articles)
List of patents
List of selected projects

30.04.2024 Gina MANDA

List of publications (selection)

BOOKS

1. **Methotrexate liposomes – a reliable therapeutic option**. Ciobanu AM, Barca M, Manda G, Burcea GTA. Chapter 10, page 171, in Liposomes, Catala A, Ed, InTech Open, 2017. ISBN: 978-953-51-3580-7
2. **Guide for the organization of the immunology laboratory**. Prof. Dr. Victor Cristea, coordinator. Auhors (in alphabetical order): Cornelia Braicu, Ioana Berindan-Neagoe, Roxana Cojocneanu-Petric, Carolina Constantin, Maria Dobre, Radu-Ionut Huică, Laura Ispravă, Gina Manda, Ionela Neagoe, Monica Neagu, Aurora Sălăgeanu, Mihaela Surcel, Cătălin Tucureanu, Cornel Ursaciuc, Mihaela Zlei. Editura Medicală Universitară "Iuliu Haţieganu", Cluj-Napoca, 2013. ISBN 978-973-693-550-3.
3. **Medical spectrometry manual**. Coordinator Prof. Dr. Mihail Eugen Hinescu. Authors Florin Mitu, Gina Manda, Vasile Preoteasa, Daniela Baconi, Ionela Neagoe. Editura Viata Medicala Romaneasca, Bucuresti, 2013. ISBN 978-973-160-074-1.
4. **Fundamental immunology.** Cornel Ursaciuc, Monica Neagu, Gina Manda. "Viata Medicala Romaneasca" Publishing House, 164 pgs., 2012.
5. **Trends in Interdisciplinary Studies Revealing Porphyrinic Compounds Multivalency Towards Biomedical Application**. Socoteanu Radu, Rica Boscencu, Anca Hirtopeanu, Gina Manda, Anabela Sousa Oliveira, Mihaela Ilie, Luis Filipe Vieira Ferreira, in Biomedical Engineering – From Theory to Applications, Reza Fazel-Rezai Ed, InTech Publishing House, p. 355-390, 2011, ISBN 978-953-307-637-9.
6. **Methods of Humoral and Cellular Immunology.** Dorel L. Radu, Crina Stavaru, Iuliana Caras, Gina Manda, Monica Neagu, Eugen Radu, Cornel Ursaciuc, Laurentiu Mircea Popescu, Universitary Publishing House "Carol Davila", Bucharest, 2006, ISBN: 973-708-084-X
7. **Interferences at the respiratory burst level between the signals delivered *in vitro* to human peripheral neutrophils *via* fMLP, complement and Fc receptors.** Marinela Bostan, Alexandra Livescu, Monica Neagu, Gina Manda, Maria Chirilă, Elena Mazâlu, A. C. Bancu, L.M. Popescu. In Immuneregulation in Health and Disease, Experimental and Clinical Aspects, M.L. Lukic, M. Colic, Marija Mostarica-Stojkovic and K. Cuperlovic Eds, Academic Press, Section 4: Host reactivity to graft, tumor and infection, Chapter 41, p. 431-438, 1997.

SELECTED SCIENTIFIC ARTICLES

1. AM Burloiu, G Manda*, D Lupuliasa, RP Socoteanu, DP Mihai, IV Neagoe, LI Anghelache, M Surcel, M Anastasescu, L Olariu, CE Gird, SF Barbuceanu, LFV Ferreira, R Boscencu. **Assessment of Some Unsymmetrical Porphyrins as Promising Molecules for Photodynamic Therapy of Cutaneous Disorders**. Pharmaceuticals 2024, 17, 62. https://doi.org/10.3390/ph17010062. IF 4.6
2. A Gkikoudi, SA Kalospyros, S Triantopoulou, S Logotheti, V Softa, C Kappas, K Theodorou, EC Laiakis, G Manda, GI Terzoudi, AG Georgakilas. **Molecular Biomarkers for Predicting Cancer Patient Radiosensitivity and Radiotoxicity in Clinical Practice**. Appl. Sci. 2023, 13(23), 12564; https://doi.org/10.3390/app132312564. IF 2.7
3. A Ciobanu, G Manda, I Neagoe, M Barca, C Balalau, EG Turcu, CM Gutu, DE Popa, DL Baconi. **The immune status of heroin addicts during treatment with methadone**. Farmacia 71 (6), 2023, https://doi.org/10.31925/farmacia.2023.6.9. IF 1.6
4. R Boscencu, G Manda, G Vasiliu, R Socoteanu, D Lupuleasa, AM Burloiu, IV Neagoe, L Olariu. **Preliminary In Vitro Evaluation of Some Porphyrins Using Human Breast Tumor Cells**. Letters in Drug Design & Discovery, 20 (8), 1040-1045, DOI:10.2174/1570180819666220318153003. IF 1.099
5. Radu M Serban, Dana Niculae*, Gina Manda*, Ionela Neagoe, Maria Dobre, Dragoș A Niculae, Mihaela Temelie, Cosmin Mustăciosu, Radu A Leonte, Livia E Chilug, Maria R Cornoiu, Diana Cocioabă, Miruna Stan, Anca Dinischiotu. **Modifications in cellular viability, DNA damage**

Manda

and stress responses inflicted in cancer cells by copper-64 ions. Frontiers in Medicine, 10: 1197846, 2023, https://doi.org/10.3389/fmed.2023.1197846. IF 9.927

6. Dragos Paul Mihai, Rica Boscencu, Gina Manda, Andreea Mihaela Burloiu, Georgiana Vasiliu, Ionela Victoria Neagoe, Radu Petre Socoteanu, Dumitru Lupuliasa. **Interaction of Some Asymmetrical Porphyrins with U937 Cell Membranes–In Vitro and In Silico Studies**. Molecules, 28(4): 1640, 2023. https://doi.org/10.3390/molecules28041640. IF 4.6
7. R Boscencu, N Radulea, G Manda, IF Machado, RP Socoteanu, D Lupuliasa, AM Burloiu, DP Mihai, LF Vieira Ferreira. **Porphyrin Macrocycles: General Properties and Theranostic Potential**. Molecules 2023, 28, 1149. https://doi.org/10.3390/molecules28031149. IF 4.6
8. Suniti Bhaumik, Marzena Łazarczyk, Norwin Kubick, Pavel Klimovich, Agata Gurba, Justyna Paszkiewicz, Patrycja Teodorowicz, Tomasz Kocki, Jarosław Olav Horbańczuk, Gina Manda, Mariusz Sacharczuk, Michel-Edwar Mickael. **Investigation of the Molecular Evolution of Treg Suppression Mechanisms Indicates a Convergent Origin**. Current Issues in Molecular Biology, 3: 628-648, 2023, https://doi.org/10.3390/cimb45010042. IF 2.976
9. Gina Manda, Elena Milanesi, Sermin Genc, Cristina Mariana Niculite, Ionela Victoria Neagoe, Bora Tastan, Elena Mihaela Dragnea, Antonio Cuadrado*. **Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis**. *Free Radical Biology and Medicine*, 190: 179-201, 2022. IF 7.4
10. Milanesi E, Dobre M, Cucoș CA, Rojo AI, Jiménez-Villegas J, Capetillo-Zarate E, Matute C, Piñol-Ripoll G, Manda G*, Cuadrado A*. **Whole blood expression pattern of inflammation and redox genes in mild cognitive impairment**. *Journal of Inflammation Research*, Volume 2021, 14: 6085—6102, doi: 10.2147/JIR.S334337. IF 6.532.
11. Milanesi E, Cucos CA, Matias-Guiu JA, Piñol-Ripoll G, Manda G, Dobre M, Cuadrado A. **Reduced blood RGS2 expression in mild cognitive impairment patients**. *Frontiers in Aging Neuroscience*, 29 September 2021, doi: 10.3389/fnagi.2021.738244. IF 5.750.
12. Cucos CA, Cracana I, Dobre M, Surcel M, Popescu BO, Tudose C, Spiru L, Manda G, Niculescu G, Milanesi E. **Sulfiredoxin-1 blood mRNA expression levels negatively correlate with hippocampal atrophy and cognitive decline**. *F1000Res*. 2022 Jan 28; 11:114. doi: 10.12688/f1000research.76191.2. IF 2.297.
13. Cucos CA, Dobre M, Dragnea EM, Manda G, Milanesi E. **Increased MYD88 blood transcript in a mouse model of Alzheimer's disease**. *BMC Neurosci*. 2022 Mar 11; 23(1):13. doi: 10.1186/s12868-022-00699-8. IF 3.288.
14. Cucos CA, Milanesi E, Dobre M, Musat IA, Manda G*, Cuadrado A*.**Altered Blood and Brain Expression of Inflammation and Redox Genes in Alzheimer's Disease, Common to APPV717I × TAUP301L Mice and Patients**; *Int J Mol Sci*. 2022 May 21;23(10):5799. doi: 10.3390/ijms23105799. IF 5.542.
15. Dobre, Maria, Rica Boscencu, Ionela V. Neagoe, Mihaela Surcel, Elena Milanesi, and Gina Manda. 2021. **Insight into the Web of Stress Responses Triggered at Gene Expression Level by Porphyrin-PDT in HT29 Human Colon Carcinoma Cells**, *Pharmaceutics* 2021, 13(7): 1032. https://doi.org/10.3390/pharmaceutics13071032. IF=6.23
16. Radu Anton Leonte, Livia Elena Chilug, Radu Șerban, Cosmin Mustăciosu, Alina Raicu, Gina Manda, Dana Niculae. **Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with 68Ga and 177Lu as Potential Theranostic Agent for Colon Cancer**. *Pharmaceutics* 2021, 13(4): 506. IF=6.23
17. Radu Petre Socoteanu, Rica Boscencu, Gina Manda, Mihai Anastasescu, Ionela Victoria Neagoe, Isabel Ferreira Machado, Octavian Dinca, Alexandru Bucur, Luis Filipe Vieira Ferreira. **Morphologic evaluation of some promising A3B porphyrinic type compounds designed for theranostic applications in cancer**. *Chemical Physics* 2021, 544: 111115. IF= 1.707
18. Elena Milanesi, Gina Manda, Maria Dobre, Elena Codrici, Ionela Victoria Neagoe, Bogdan Ovidiu Popescu, Ovidiu Alexandru Bajenaru, Luiza Spiru, Catalina Tudose, Gabriel-Ioan Prada, Eugenia Irene Davidescu, Gerard Piñol-Ripoll, Antonio Cuadrado. **Distinctive under-expression profile of inflammatory and redox genes in the blood of elderly patients with cardiovascular disease**. *Journal of Inflammation Research* 2021, 14: 429. IF=4.953

19. Norwin Kubick, Patrick C Henckell Flournoy, Ana-Maria Enciu, Gina Manda, Michel-Edwar Mickael. **Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer's Disease**. *Pharmaceutics*, 12(9), 880, 2020. IF = 4.421
20. Norwin Kubick, Patrick C. Henckell Flournoy, Pavel Klimovich, Gina Manda, Michel-Edwar Mickael. **What has single-cell RNA sequencing revealed about microglial neuroimmunology?** *Immunology, Inflammation and Disease* 2020, https://doi.org/10.1002/iid3.362. IF= 2.5
21. Gina Manda, Antonio Cuadrado, **The transcription factor NRF2 shapes the identity of radio-resistant tumor cells**. *Journal of Cell Identity* 2020, 1: 49–81;DOI: 10.47570/joci.2020.004).
22. Livia Elena Chilug, Dana Niculae, Radu Anton Leonte, Alexandrina Nan, Rodica Turcu, Cosmin Mustaciosu, Radu Marian Serban, Vasile Lavric, Gina Manda. **Preclinical Evaluation of NHS-Activated Gold Nanoparticles Functionalized with Bombesin or Neurotensin-Like Peptides for Targeting Colon and Prostate Tumours**. *Molecules* 2020, 25: 3363. IF = 3.267
23. Antonio Cuadrado, Marta Pajares, Cristina Benito, José Jiménez-Villegas, Maribel Escoll, Raquel Fernández-Ginés, Angel J. Garcia Yagüe, Diego Lastra, Gina Manda, Ana I. Rojo, Albena T. Dinkova-Kostova. **Can Activation of NRF2 Be a Strategy against COVID-19**? *Trends in Pharmacological Sciences*, 1738, 22 July 2020. IF = **11.523**
24. Marta Pajares, Ana I. Rojo, Gina Manda, Lisardo Boscá, Antonio Cuadrado. **Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications**. *Cells* 2020, 9(7), 1687. IF = 4.366
25. Norwin Kubick, Marta Pajares, Ioana Enache, Gina Manda, Michel-Edwar Mickael. **Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach**. *Molecules* 2020, 25(9): 2155. IF = 3.267
26. Gina Manda, Cristian Postolache, Ionela Victoria Neagoe, Andreea Csolti, Elena Milanesi, Maria Dobre. **The expression profile of redox genes in human monocytes exposed *in vitro* to γ radiation**. *Radiation Physics and Chemistry* 2019, 170: 108634. IF =1.435
27. Gina Manda, Ana I. Rojo, Elena Martínez-Klimova , José Pedraza-Chaverri, Antonio Cuadrado. **Nordihydroguaiaretic acid: from herbal medicine to clinical development for cancer and chronic diseases**. *Frontiers Pharmacology* 2019, 11:151. IF = 3.845
28. Alina-Andreea Zimta, Vlad Schitcu, Eugen Gurzau, Crina Stavaru, Gina Manda, Stefan Szedlacsek, Ioana Berindan-Neagoe. **Biological and molecular modifications induced by cadmium and arsenic during breast and prostate cancer development**. *Environmental Research* 2019, 178: 108700, https://doi.org/10.1016/j.envres.2019.108700. IF = 5.026
29. Asavei T, Bobeica M, Nastasa V, Manda G, et al. **Laser-driven radiation: Biomarkers for molecular imaging of high dose-rate effects**. *Medical Physics* 2019, 46(10): e726-e734. IF = 2.617
30. Robledinos-Anton N, Fernandez-Gines R, Manda G, Cuadrado A. **Activators and inhibitors of NRF2: A review of their potential for clinical development**. *Oxid Med Cell Longev* 2019, 2019:9372182. IF = 4.868
31. Radu Albulescu, Adrian-Claudiu Popa, Ana-Maria Enciu, Lucian Albulescu, Maria Dudau, Ionela Daniela Popescu, Simona Mihai, Elena Codrici, Sevinci Pop, Andreea-Roxana Lupu, George E Stan, Gina Manda, Cristiana Tanase. **Comprehensive In Vitro Testing of Calcium Phosphate-Based Bioceramics with Orthopedic and Dentistry Applications**. *Materials* 2019, 12(22): 3704. IF = 2.972
32. Natalia Radulea, Rica Boscencu, Radu Socoteanu, Gina Manda, Ionela Victoria Neagoe. **The Effect of Some Amphiphilic Porphyrins on the Transmembrane Potential of Cultured L929 Cells**. *Revista de Chimie* 2019, 70(4): 1288-1292. IF = 1.605
33. Gina Manda, Mihail Eugen Hinescu, Ionela Victoria Neagoe, Luis Filipe Vieira Ferreira, Rica Boscencu, Paul Vasos,Selma Huveyda Basaga, Antonio Cuadrado. **Emerging Therapeutic Targets in Oncologic Photodynamic Therapy**. *Current Pharmaceutical Design* 2019, 24(44): 5268-5295. IF=2.962
34. Panait ME, Chilug L, Negoita V, Busca A, Manda G, Niculae D, Dumitru M, Gruia MI. **Biological effects induced by 68Ga - conjugated peptides in human and rodent tumor cell lines**. *Molecular Imaging and Biology* 2018, 25: 979–987. IF=3.466

35. Boscencu R, Socoteanu RP, Manda G et al. **New A3B porphyrins as potential candidates for theranostic. Synthesis and photochemical behaviour**. *Dyes and Pigments* 2018, 160: 410-417. IF=3.767
36. Codeanu C, Popescu CC, Mogosan C, Enache L, Manda G, Berghea F, Groseanu L, Predeteanu D. **Targeting interleukin 17 in the treatment of rheumatoid arthritis**. *Farmacia* 2018, 66(3): 390-398. IF=1.507
37. Antonio Cuadrado, Gina Manda, Ahmed Hassan, et al. **Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach.** *Pharmacological Reviews* 2018, 70(2):348-383. **IF=17.17**
38. Pietro Ghezzi, Luciano Floridi, Diana Boraschi, Antonio Cuadrado, Gina Manda, Snezana Levic, Fulvio D'Acquisto, Alice Hamilton, Toby J Athersuch, Liza Selley. **Oxidative stress and inflammation induced by environmental and psychological stressors: A biomarker perspective**, *Antioxidants & redox signaling* 2018, 28(9): 852-872. IF= 6.337
39. Burns JS, Manda G. **Metabolic Pathways of the Warburg Effect in Health and Disease: Perspectives of Choice, Chain or Chance**, *International Journal of Molecular Science* 2017, 18(12):2755. IF=3.482
40. Rica Boscencu, Gina Manda, Natalia Radulea, Radu Petre Socoteanu, Laura Cristina Ceafalan, Ionela Victoria Neagoe, Isabel Ferreira Machado, Selma Huveyda Basaga, Luís Filipe Vieira Ferreira. **Studies on the Synthesis, Photophysical and Biological Evaluation of Some Unsymmetrical Meso-Tetrasubstituted Phenyl Porphyrins**, *Molecules* 2017, 22(11): 1815. IF=2.988
41. Chilug LE, Leonte RA, Barbinte Patrascu ME, Ion AC, Tuta CS, Raicu A, Manda G, Niculae D. **In vitro binding kinetics study of gold nanoparticles functionalized with 68Ga-DOTA conjugated peptides.** *J Radioanal Nucl Chem* 2017, 3(2):1485-1493. IF = 1.282
42. Barca M, Manda G, Ciobanu AM, Balalau C, Lupuleasa D, Traian G, Dragomiroiu GTAB, Pop A, Popa DE, Baconi DL. **Immunomodulatory effects of methadone following methotrexate therapy in a rat model of arthritis**, *Farmacia* 2017, 65(3):423-428. IF = 1.348
43. Asavei T, Tomut M, Bobeica M, Aogaki S, Cernaianu MO, Ganciu M, Kara S, Manda G, et al. **Materials in extreme environments for energy, accelerators and space applications at ELI-NP**, *Romanian Reports in Physics* 2016, 68(Suppl): S275–S347. IF = 1.367
44. Checheriţă IA, Manda G, Hinescu ME, Peride I, Niculae A, Bilha S, Gramaticu A, Voroneanu L, Covic A. **New molecular insights in diabetic nephropathy**. *International Urology and Nephrology* 2016, 48(3): 373-387. IF = 1.292
45. Dumitrache F, Morjan IG, Fleaca CI, Badoi A, Manda G, Pop S, Marta DS, et.al. **Highly magnetic Fe2O3 nanoparticles synthesized by laser pyrolysis used for biological and heat transfer applications.** *Applied Surface Science* 2015, 336: 297–303. IF = 2.711
46. Socoteanu R, Manda G, Boscencu R, Vasiliu G, Anabela Sousa Oliveira. **Synthesis, spectral analysis and preliminary in vitro evaluation of some tetrapyrrolic complexes with 3d metal ions**. *Molecules* 2015, 20(9): 15488-15499, doi:10.3390/molecules200915488. IF = 2.465
47. Manda G, Isvoranu G, Comanescu MV, Manea A, Debelec Butuner B, Korkmaz KS. **The redox biology network in cancer pathophysiology and therapeutics**. *Redox Biology* 2015, 5: 347-357. IF = 6.235
48. Manea SA, Constantin A, Manda G, Sasson S, Manea A. **Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms**. *Redox Biol*ogy 2015, 5: 358-366. IF = 6.235
49. Manda G, Mocanu MA, Marin DE, Taranu I. **Dual Effects Exerted in Vitro by Micromolar Concentrations of Deoxynivalenol on Undifferentiated Caco-2 Cells.** *Toxins* 2015, *7*(2), 593-603. IF = 3.571
50. Manda G, Checherita AI, Comanescu MV, Hinescu ME. **Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes.** *Mediators of Inflammation* 2015, 2015, Article ID 604208. IF = 3.418
51. Margina D, Ilie M, Manda G, Neagoe I, Danciulescu-Miulescu R, Purdel CD, Gradinaru D. **In vitro effects of prolonged exposure to quercetin and epigallocatechin gallate of the**

Manda

peripheral blood mononuclear cell membrane. *Cellular and Molecular Biology Letters* 2014, 19: 542-560. IF = 1.782

52. Margina D, Gradinaru D, Manda G, Neagoe I, Ilie M. **Membranar effects exerted in vitro by polyphenols – quercetin, epigallocatechin gallate and curcumin – on HUVEC and Jurkat cells, relevant for diabetes mellitus**. Food Chem Toxicol, 61:86-93, 2013, pii: S0278-6915(13)00155-5. IF = 2.610
53. Nechifor MT, Niculiţe CM, Urs AO, Regalia T, Mocanu M, Popescu A, Manda G, Dinu D, Leabu M. **UVA Irradiation of Dysplastic Keratinocytes: Oxidative Damage versus Antioxidant Defense**. *Int. J. Mol. Sci,* 13, 16718-16736, 2012**.** IF = 2.464
54. Marin DE, Taranu I, Burlacu R, Manda G, Motiu M, Neagoe I, Dragomir C, Stancu M, Calin L. **Effects of zearalenone and its derivatives on porcine immune response**. *Toxicology In Vitro*. 25(8):1981-1988, 2011. IF = 2.775
55. Taranu I, Daniela E. Marin DE, Manda G, Motiu M, Ionela Neagoe I, Cristina Tabuc C, Stancu M, Olteanu M. **Assessment of the potential of a boron–fructose additive in counteracting the toxic effect of *Fusarium* mycotoxins**. *Br J Nutrition*, 106(3): 398-407, 2011. IF = 3.013
56. Rica Boscencu, Mihaela Ilie, Radu Socoteanu, Anabela Sousa Oliveira, Carolina Constantin, Monica Neagu, Gina Manda, Luis Filipe Vieira Ferreira. **Synthesis, Basic Spectral and Biological Evaluation of Some Copper (II) Mesoporphyrinic Complexes**. *Molecules,* 15(5), 3731-3743, 2010. IF = 1.988
57. Lidia Matei, Ionela Neagoe, C. Postolache, C.V. Tanase, G. Bubueanu, Gina Manda. **In vitro and in vivo Radiometrical Studies For Evaluation of New Nucleoside Analogue Behavior.** *J. Label Compd. Radiopharm*. **53**: 294-299, 2010. IF = 1.096
58. Gina Manda, Marina Tamara Nechifor, Teodora-Monica Neagu. **Reactive Oxygen Species, Cancer and Anti-Cancer Therapies**. *Current Chemical Biology*, 3(1): 342-366, 2009.
59. Gina Manda, Monica Neagu, Carolina Constantin, Ionela Neagoe, Catalin Codreanu. **Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one-month therapy with leflunomide.** *Rheumathology International,* 29(8): 937-946, 2009**.** IF = 1.493

LIST OF PATENTS

OSIM patent 131946/2019 Tetrapyrrolic compound with theranostic applications and obtaining process – authors: Boscencu R, Manda G, Socoteanu RP, Hinescu ME, Radulea N, Neagoe IV, Ferreira LFV.

OSIM patent 01030/2017 Porphyrin derivative for theranostic use – authors: Boscencu R, Manda G, Socoteanu RP, Hinescu ME, Neagoe I, Olariu L, Dumitriu B.

OSIM patent 125018 B1/2015 Biofunctionalized porphyrinic compound – authors: Socoteanu R, Boscencu R, Nacea V, Constantin C, Manda G, Neagu M, Ilie M, Oliveira AS, Ferreira LFV, published in RO-BOPI 4/30.04.2015

OSIM patent 126761 B1/2014 Asymmetrically substituted porphyrinic compound, as a photosensitizing agent, used in cancer diagnosis and its preparation process – authors: Boscencu R, Socoteanu R, Constantin C, Neagu M, Manda G, Ilie M, Nacea V, Gird CE, Oliveira AS, Ferreira LFV.

OSIM patent 128433 A2/2013 Procedure for the identification and dosing by HPLC of leflunomide in the patients' blood – authors: Negrei C, Baconi D, Margină D, Bălănescu A, Berghea F, Ilie M, Manda G, published in RO-BOPI 5/30.05.2013

OSIM patent 123419 B1/2012 Asymmetrically substituted tetrapyrrolic compound, obtaining process and biological evaluation at cellular level – authors: Boscencu R, Socoteanu R, Nacea V, Constantin C, Manda G, Neagu M, Ilie M, Baconi DL, Oliveira AS, Ferreira LFV, published in RO-BOPI 3/30.03.2012

LIST OF SELECTED RESEARCH PROJECTS

Project/Research Program	Function	Duration
International projects		
EURAMET / 21GRD02 BIOSPHERE Metrology for Earth Biosphere: Cosmic rays, ultraviolet radiation and fragility of ozone shield, ccordinator Faton Krasniqi, Physikalisch-Technische Bundesanstalt, Braunschwig, Germany, 22 European institutions involved, WP4 member and task coordinator,	WP4 coordinator of Task 4.2	2022-2025
AO-2017-IBER (ESA-HRE-UL-LE-0003) Redox signalling and the transcription factor NRF2 as therapeutic target for counteracting the deleterious effects of spaceflight environment, financed by ESA through the AO-IBER program. Partner: GSI Center for Heavy Ion Research, Germany	Scientific coordinator	2017-2021
POC P37_732, contract 29/2016 Knowledge transfer in redox biology for developing advanced molecular tools in neurodegenerative diseases - focus on the signature of Nrf2 transcription factor in diagnosis and therapy, coordinated by Prof. Antonio Cuadrado (Autonomous University of Madrid, Spain)	Coordinator of cellular studies and representative of the project director in Ronaia	2016-2020
M-Era.NET (contract 52/2014) Advanced theranostic approach in cancer combining photodynamic therapy and nanoparticles – NANOTHER, coordinated by Prof. Luis Filipe Vieira Ferreira (Lisbon University, Portugal)	Leader of WP5 Preclinical study	2016-2019
COST Action CA15107 Multi-Functional Nano-Carbon Composite Materials Network-MultiComp, coordinated by Dr. Sharali MALIK (Karlsruhe Institute of Technology, Institute of Nanotechnology)	Vice-leader of WG3-Characterization, Health, Safety and Environment	2015-2019
COST Action BM1203 EU-ROS coordinated by Prof. Andreas DAIBER (University Medical Center Mainz, Germany)	Member of the management team	2012-2016
MNT-ERA NET (Ref 419) Tetrapyrrole nanostructures towards fluorescent molecular markers for biomedicine. Cooperation with Portugal (Instituto Superior Técnico – Technical University of Lisbon – Centro de Química-Física Molecular e Instituto de Nanociência e Nanotecnologia)	Investigator	2010-2012
Bilateral Cooperation Program Greece-Romania, nr. 7285/02 "Victor Babes" National Institute of Pathology, Romania, and National & Kapodistrian University of Athens, Greece Immunomodulating potential of prothymosin alpha and its fragments on lymphocyte functions in vitro. Analysis of the mechanisms of action of the polypeptide and specific peptides spanning its primary structure, coordinated by Dr. Ourania Tsitsilonis (Kapodistrian University of Athens, Greece***)***	Investigator	2003-2005
Clinical trial LOR/VIR/PO3/002 –Lorus Company, Canada Clinical Trial phase III, double blind, multicenter, randomized study in chemonaive patients with locally advanced or metastatic pancreatic	Investigator	2003-2005



cancer to compare a combination therapy of Virulizin® plus Gemcitabine versus placebo plus Gemcitabine; optional second-line therapy may include continuation of Virulizin® or placebo, alone or in combination with 5-Florouracil		
COST Actions		
COST / COST Action CA20121 Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	Vice-chair Scientific Representative of the Grant Holder	2021-2025
COST / COST Action CA19114 Network for Optimized Astatine labeled Radiopharmaceuticals	Member	2020-2024
COST / COST Action CA15107 Multi-Functional Nano-Carbon Composite Materials Network-MultiComp, coordinated by Dr. Sharali MALIK (Karlsruhe Institute of Technology, Institute of Nanotechnology)	Vice-leader of WG3-Characterization, Health, Safety and Environment	2015-2019
COST / COST Action BM1203 EU-ROS coordinated by Prof. Andreas DAIBER (University Medical Center Mainz, Germany)	Member of the management team	2012-2016
European Social Fund "Human Resources"		
POSDRU/81/3.2/S/59497 Vocational and organizational training for immunological laboratory employees by implementing high tech and quality management-IMUNOLAB. Coordinator Prof. Victor Cristea; cooperation with the University of Goteborg	Teaching coordinator	2010-2013
POSDRU 81/3.2/S/58819 Professional formation system of the medical personnel in the field of new technologies applicable in the health system-TDM; coordinator Acad. Laurentiu M. Popescu	Partnership manager	2010-2013
POSDRU/89/1.5/S/141531 Development of human resources – PhD students and postodoctoral researchers-DPD (Dezvoltarea resurselor umane - doctoranzi si postdoctoranzi - pentru cercetare de excelenta in domeniile sanatate si biotehnologii-DPD), coordinator Acad. Laurentiu M. Popescu	Tutor	2014-2015
POSDRU/159/1.5/S/135760 Career profile: Romanian Researcher - CERO (Profil de Carieră: Cercetător Român - CERO); coordinator: Conf. Dr. Ismail Gener	Tutor	2014-2015
National projects		
PN 23.16.02.01/2023 Stress genes as therapeutic targets in the radiotherapy and photodynamic therapy of colon carcinoma	Coordinator	2023-2026
PED / 637PED/2022 Customized photodynamic protocol with innovative porphyrins and redox modulators in premalignant cutaneous disorders - preclinical demonstration	Coordinator	2022-2024
ELI-RO / ELI-09 /2020 Advanced biological methods for investigating stress responses of normal and pre-leukemic cells under irradiation at ELI-NP – applications for astrobiology and FLASH radiotherapy (CELLI)	Coordinator	2020-2023
PN 19.29.02.02 A systems biology approach for developing new redox therapies for increasing the radiotherapy efficacy	Project coordinator	2019-2022

PCCDI 35 /2018 Genomic mapping of population from areas contaminated with radioisotopes and heavy metals aiming to increase national security (ARTEMIS)	Component project 3 coordinator	2018-2021
PCCDI 64/2018 Development of radiopharmaceuticals and nuclear techniques in oncology, for imagistic diagnosis and personalized treatment at molecular level (ONCORAD)	Component project 3 coordinator	2018-2021
PN 18.21.01.02 / 2018 Molecular signature of the transcription factor NRF2 – new therapeutic approaches for increasing radiotherapy efficacy in cancer	Project coordinator	2018
ELI-RO 13-ELI/2016 Development of the national technological platform for investigating the interaction of complex biogical systems with space radiations in the context of ELI-NP / ABEL (ASTRO-BIO-ELI)	Scientific coordinator	2016-2019
RO-CERN E05/2014 Advanced technologic platform for preclinical studies on radiopharmaceuticals	Scientific coordinator	2014-2016
PN 16.22.03.03 Molecular networks connecting NLRP3 inflammasome and redox signaling in rheumatoid arthritis	Project coordinator	2016-2017
PN 09.33.02.07 TNF-alfa, TGF-beta, VEGF and EGFR - new biomarkers in molecular therapies in rheumatoid arthritis	Project coordinator	2013-2015
PNCDI2 CEEX 61-018/2007 Novel nucleoside analogs potentially active in cancer therapy – from synthesis to cellular and molecular targets	Project coordinator	2007-2010
Viasan 229/2003 Immunomodulatory signals delivered *in vitro* by opioid receptors in rheumatoid arthritis	Project coordinator	2003-2005
Viasan 091/2001 Dynamic of functional cellular and molecular parameters of rheumatoid arthritis patients treated with inhibitors of nucleotide synthesis (leflunomide and methotrexate)	Project coordinator	2001-2004
CALIST 1087/ 2004 System of cellular immunology methods: validation and applications in toxicology and pharmacology	Project coordinator	2004-2006
PCCA 124/2014 The Th17 network - predictor of response to anti-TNFα therapy in rheumatoid arthritits	Partner co-director	2014-2016
PNCDI2 102/2012 Impact of feed co-contamination and mitigating solutions to increase feed safety, animal health and food quality	Partner co-director	2012-2015
PNCDI2 42-152/2008 New biological research and methods to assess early toxicity of immunosuppressant therapy in rheumatic diseases	Partner co-director	2008-2011
PNCDI2 52-122/2008 Security and quality of feeding stuffs and animal products by nutritional solutions for diminishing negative effects of mycotoxins, natural contaminants of farm animals and humans	Partner co-director	2008-2011
PNCDI2 61-037/2008 Development of a QSAR system for modeling the activity of anti-tumor and anti-rheumatic therapeutic agents in individualized therapies	Partner co-director	2007-2010
CEEX 36/2005 Radioactive compounds in molecular biology, pharmacology, and toxicology	Partner co-director	2005-2008
CEEX 27/2005 Psychosomatic changes in drug-addicts during substitution therapy	Partner co-director	2005-2008

CEEX 25/2005 Mycotoxins produced by Fusarium fungi and the food chain – new methods to characterize and prevent toxicity	Partner co-director	2005-2008
Biotech 378/2003 Modulation of apoptosis with biologically active substances in relation to oxidative stress and membrane processes	Partner co-director	2003-2005
Biotech 4745/2004 Studies regarding the signal transduction mechanisms of physiological cellular receptors: modulation with natural biologically active substances with therapeutic potential	Partner co-director	2003-2005